NasdaqCM - Nasdaq Real Time Price USD

PAVmed Inc. (PAVM)

Compare
0.6490
+0.0500
+(8.35%)
At close: January 15 at 4:00:00 PM EST
0.6489
-0.00
(-0.02%)
After hours: 7:54:25 PM EST

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Lishan Aklog M.D. Chairman & CEO 953.2k -- 1966
Mr. Dennis M. McGrath CPA President & CFO 673.5k -- 1957
Mr. Shaun M. O'Neill M.B.A. Executive VP & COO 498k -- 1982
Mr. Michael Adam Gordon Executive VP, General Counsel & Secretary 710.5k -- 1975
Dr. Brian J. deGuzman M.D. Executive VP, Chief Technology & Compliance Officer 427.6k -- 1965
Dr. Suman M. Verma M.D., Ph.D. Senior VP of Molecular Genetics & Chief Scientific Officer -- -- --
Michael Parks Vice President of Investor Relations -- -- --
Dr. Deepika A. Lakhani Ph.D. Senior VP, Chief Regulatory & Quality Officer -- -- --
Dr. Victoria T. Lee M.D. Senior VP & Chief Medical Officer -- -- --

PAVmed Inc.

360 Madison Avenue
25th Floor
New York, NY 10017
United States
917-813-1828 https://www.pavmed.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
107

Description

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Corporate Governance

PAVmed Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

March 24, 2025 at 8:00 PM UTC - March 28, 2025 at 8:00 PM UTC

PAVmed Inc. Earnings Date

Recent Events

January 15, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 7, 2025 at 12:00 AM UTC

DEFA14A: Proxy Statements

December 20, 2024 at 12:00 AM UTC

S-3: Offering Registrations

December 6, 2024 at 12:00 AM UTC

DEF 14A: Proxy Statements

November 29, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 21, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 14, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 16, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 13, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 12, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

Related Tickers